Expert Recommendations on the Use of a New Hyaluronic Acid Injectable for the Aesthetic Treatment of the Chin and Lower Face.

The Restylane® portfolio of hyaluronic acid (HA) fillers comprises a broad range of products, each with a unique combination of gel strength/firmness and flexibility. Restylane® Shaype™ (HASHA) is a new HA injectable produced with NASHA-HD™ technology and the most recent addition to the Restylane portfolio. NASHA-HD is an evolution of the NASHA™ platform that adds more HA and uses a more efficient cross-linking even though the degree of modification is kept low.

Efficacy and Safety of RelabotulinumtoxinA Liquid Botulinum Toxin in the Treatment of Lateral Canthal Lines: Results From the Phase 3 READY-2 Study.

Background: RelabotulinumtoxinA (RelaBoNT-A) is a complex-free, ready-to-use, liquid botulinum toxin A.

Objective: Efficacy/safety of RelaBoNT-A treatment for lateral canthal lines (LCL).

Methods: Randomized adults received RelaBoNT-A (30 U/side; n = 230) or placebo (n = 73) during a 6-month, double-blind, Ph3 study (Relabotulinumtoxin Aesthetic Development Study-2 [READY-2]).

Presence-absence surveys yield spatially imprecise information about nesting sites of an endangered, forest-nesting seabird.

Presence-absence surveys are frequently used to monitor populations of rare and elusive species. Such data may also be used as a proxy for breeding activity, but links between presence-absence data and higher-order processes must be validated to determine their reliability. The Marbled Murrelet (Brachyramphus marmoratus) is a threatened seabird that nests in older-aged forests along the Pacific Coast.

Skeletal muscle hypertrophy and enhanced mitochondrial bioenergetics following electrical stimulation exercises in spinal cord injury: a randomized clinical trial.

We examined the combined effects of neuromuscular electrical stimulation-resistance training (NMES-RT) and functional electrical stimulation-lower extremity cycling (FES-LEC) compared to passive movement training (PMT) and FES-LEC on mitochondrial electron transport chain (ETC) complexes and citrate synthase (CS) in adults with SCI. Thirty-two participants with chronic SCI were randomized to 24 weeks of NMES-RT + FES [n = 16 (14 males and 2 females) with an age range of 20-54 years old] or PMT + FES [n = 16 (12 males and 4 females) with an age range of 21-61 years old]. The NMES-RT + FES group underwent 12 weeks of surface NMES-RT using ankle weights followed by an additional 12 weeks of FES-LEC.

Reduction of masseter muscle prominence after treatment with onabotulinumtoxinA: Primary results from a randomized phase 2 study.

Background: OnabotA is used to treat masseter muscle prominence (MMP).

Objective: To assess the safety and efficacy of OnabotA for MMP in a randomized study.

Methods: This 12-month, multicenter, double-blind, placebo-controlled, phase 2 study randomized adults (18-50 years of age) with marked/very marked bilateral MMP (≥4 on the Masseter Muscle Prominence Scale [MMPS]) to OnabotA (24, 48, 72, or 96 U) or placebo; retreatment occurred at day 180 if MMPS ≥4.